"Interesting" is an understatement. Other than Quartelies and an...

"Interesting" is an understatement. Other than Quartelies and an Annual Report, there has only been one (yes, only one) price-sensitive ann reported by the company since March of last year (updated data on PTX-100)! So, it is no wonder that the SP has slid to where it is now. It makes me wonder whether GS has got himself on the board to give it a shake up or whether he (and David Kenley) is committed to seeing OmniCAR back on the front burner or have involvement in the development of PTX-100.

The last the market heard is that OmniCAR required further optimisation and CellPryme was being evaluated by 3rd parties and in pre-clinical testing in NK cells. Interesting to see that two members of the Lateral Pharma team were involved in the spin-off of Polynovo: https://announcements.asx.com.au/asxpdf/20070831/pdf/3149rq2v0yythz.pdf

I guess we will be finding out soon enough what the motivation is behind the appointment of GC.